| Literature DB >> 35604365 |
S Pereira1, S Carmi2, G Altarescu3, J Austin4, D Barlevy1, A Hershlag5,6, E Juengst7, K Kostick-Quenet1, E Kovanci8, R B Lathi9, M Mukherjee1,10, I Van den Veyver11,12, O Zuk13, G Lázaro-Muñoz14,15, T Lencz16,17,18.
Abstract
Recent advances in developing polygenic scores have made it possible to screen embryos for common, complex conditions and traits. Polygenic embryo screening (PES) is currently offered commercially, and though there has been much recent media and academic coverage, reproductive specialists' points of view have not yet been prominent in these discussions. We convened a roundtable of multidisciplinary experts, including reproductive specialists to discuss PES and its implications. In this Opinion, we describe four clinically relevant issues associated with the use of PES that have not yet been discussed in the literature and warrant consideration.Entities:
Keywords: PRS; embryo screening; genetic screening; genomic risk scores; polygenic embryo screening; polygenic risk scores; trait screening
Mesh：
Year: 2022 PMID： 35604365 PMCID： PMC9247413 DOI： 10.1093/humrep/deac110
Source DB: PubMed Journal: Hum Reprod ISSN： 0268-1161 Impact factor: 6.353